Interestingly, in head and neck cancer models, molecular disruption of NBS1 increased cisplatin sensitivity in xenograft models, providing in vivo evidence that NBS1 is a predictive biomarker in solid tumors [36,37]. This evidence concerns the gene NBN and head and neck cancer.